Global Acute Pancreatitis Market Projected to Reach USD 10.59 Billion by 2031 | Growing at a CAGR of 5.8%
Category : Healthcare | Published Date : Nov 2024 | Type : Press Release
Acute Pancreatitis Market Scope & Overview:
In the newly published report, Consegic Business Intelligence states that the Acute Pancreatitis Market was valued at USD 6.73 Billion in 2023 and is expected to reach USD 10.59 Billion by 2031, growing at a CAGR of 5.8% during the forecast period from 2023 to 2031. Acute pancreatitis involves sudden inflammation of the pancreas, often characterized by severe abdominal pain. It requires immediate medical intervention to prevent complications. The market encompasses various treatment options, including medications, surgery, and endoscopic therapies aimed at managing symptoms and restoring pancreatic function effectively.
The report comprises the Acute Pancreatitis Market Share, Size & Industry Analysis, By Type (Mild Acute Pancreatitis, Moderately Severe Acute Pancreatitis, Severe Acute Pancreatitis), By Treatment (Medication, Surgery, Endoscopic Therapy, Others), By Route of Administration (Oral, Intravenous, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By End User (Hospitals, Specialty Clinics, Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2024–2031.
The report contains detailed information on Acute Pancreatitis Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profile, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
Increased use of imaging techniques like CT scans and MRI for accurate diagnosis and assessment of acute pancreatitis is driving market growth. However, high costs associated with hospitalization and treatment procedures present significant challenges.
Segmental Analysis :
By Type, the market is divided into Mild Acute Pancreatitis, Moderately Severe Acute Pancreatitis, and Severe Acute Pancreatitis.
- Mild Acute Pancreatitis accounted for the largest revenue share of 51.48% in 2023, driven by its high prevalence and manageable treatment approaches, often requiring minimal intervention.
- Severe Acute Pancreatitis is projected to register the fastest CAGR, owing to the need for intensive care and advanced treatment due to high complication risks.
By Treatment, the market is segmented into Medication, Surgery, Endoscopic Therapy, and Others.
- Medication held the largest share in 2023, as it is foundational for managing symptoms, including pain relief and enzyme supplementation.
- Endoscopic Therapy is anticipated to grow at the fastest rate, supported by advancements in minimally invasive procedures like ERCP for bile duct complications.
By Route of Administration, the segments include Oral, Intravenous, and Others.
- Intravenous Administration was the largest segment in 2023, preferred for its rapid relief and stabilization of patients in emergency settings.
- Oral Administration is expected to grow at the fastest rate, favored for mild cases and continued care following hospital discharge.
By Distribution Channel, the market includes Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies.
- Hospital Pharmacies dominated the market in 2023, benefiting from their association with immediate and essential acute care services.
- Online Pharmacies are projected to register the fastest growth, driven by increasing adoption of digital healthcare services and convenience in follow-up medication delivery.
By End User, the segments are Hospitals, Specialty Clinics, and Others.
- Hospitals accounted for the largest share in 2023 due to their capability to provide comprehensive acute care, including intensive monitoring and surgical interventions.
- Specialty Clinics are expected to grow rapidly, offering focused outpatient services and follow-up care, reducing the burden on hospital infrastructure.
Based on regions, the global market is segmented into North America, Europe, Asia-Pacific, Middle East & Africa, and Latin America.
- North America led the market, projected to reach over USD 3.75 Billion by 2031, supported by a strong healthcare system and high incidence rates linked to lifestyle factors.
- Asia-Pacific is expected to witness the fastest growth, with China contributing significantly to the region's market, driven by rising cases and improving healthcare infrastructure.
| Report Attributes | Report Details |
| Study Timeline | 2018-2031 |
| Market Size in 2031 | USD 10.59 Billion |
| CAGR (2024-2031) | 5.8% |
| By Type | Mild Acute Pancreatitis, Moderately Severe Acute Pancreatitis, Severe Acute Pancreatitis |
| By Treatment | Medication, Surgery, Endoscopic Therapy, Others |
| By Route of Administration | Oral, Intravenous, Others |
| By Distribution Channel | Hospital Pharmacies, Retail Pharmacies, Online Pharmacies |
| By End User | Hospitals, Specialty Clinics, Others |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape of the Acute Pancreatitis Market includes key players focused on research, product development, and strategic partnerships to maintain a strong market position. The analysis of the competitive landscape highlights major innovators, leading pharmaceutical companies, and emerging players, all examined for their strengths and potential value addition. The report features comprehensive profiles, market share analysis, mergers, and recent strategic developments.
List of prominent players in the Acute Pancreatitis Industry:
- AbbVie Inc. (United States)
- Pfizer Inc. (United States)
- Novartis AG (Switzerland)
- Sanofi (France)
- AstraZeneca plc (United Kingdom)
- Johnson & Johnson (United States)
- GlaxoSmithKline plc (United Kingdom)
- Takeda Pharmaceutical Company Limited (Japan)
- Bayer AG (Germany)
- Merck & Co., Inc. (United States)
Recent Industry Developments :
- March 2021: CalciMedica completed a merger with Graybug Vision, focusing on advancing its lead product, Auxora™, for clinical trials targeting acute pancreatitis and related inflammatory conditions.
- June 2020: Novartis announced the initiation of a new clinical program for the early detection and treatment of acute pancreatitis, emphasizing novel diagnostic approaches.
